The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of March 19, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 19.
Number 5: In the latest episode of our podcast, “Not So Different,” Christine Simmon of the Biosimilars Council explains why her organization supports the CREATES Act.
Number 4: Celltrion has granted marketing rights for its trastuzumab in 7 European nations to Mundipharma.
Number 3: A recent study showed that patients with rheumatoid arthritis who use infliximab have a higher discontinuation rate due to disease remission than those patients who use other biologics.
Number 2: The FDA’s Center for Drug Evaluation and Research has launched its pilot effort to publicly release clinical study report data from pivotal clinical trials.
Number 1: An insurer is backing away from a plan to institute a nonmedical switch from brand-name Remicade to biosimilar Inflectra.
Finally, last week, our e-newsletter asked for your thoughts on which stakeholder group has the most influence on biosimilar acceptance.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.